Barend J Sikkema
Overview
Explore the profile of Barend J Sikkema including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
5
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sikkema B, Baart S, Paats M, Smit E, Schols A, Mathijssen R, et al.
J Clin Oncol
. 2024 Dec;
43(6):641-650.
PMID: 39661917
Purpose: Weight gain is a known adverse event (AE) of alectinib. This study evaluates the progression of actual weight gain over time and explores its association with baseline characteristics. Methods:...
2.
Sikkema B, Mathijssen R, Robbrecht D, Perera T, Koolen S, de Bruijn P
J Pharm Biomed Anal
. 2024 Jan;
240:115962.
PMID: 38211518
DO-2 is a highly selective MNNG HOS transforming (MET) inhibitor. This deuterated drug is thought to diminish the formation of the Aldehyde Oxidase 1 inactive metabolite M3. For various reasons,...
3.
de Leeuw S, Pruis M, Sikkema B, Mohseni M, Veerman G, Paats M, et al.
J Thorac Oncol
. 2023 Mar;
18(8):1017-1030.
PMID: 37001858
Introduction: Alectinib is a standard-of-care treatment for metastatic ALK+ NSCLC. Weight gain is an unexplored side effect reported in approximately 10%. To prevent or intervene alectinib-induced weight gain, more insight...
4.
Meertens M, Muntinghe-Wagenaar M, Sikkema B, Lopez-Yurda M, Retel V, Paats M, et al.
Front Oncol
. 2023 Mar;
13:1136221.
PMID: 36969063
Background: Alectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma (NSCLC) and an anaplastic lymphoma kinase (ALK) fusion. A shorter median progression-free survival (mPFS) was observed...